What is Exelixis's other non-current assets?

Exelixis (EXEL) reported other non-current assets of $0 in Q1 2026.

What is the long-term trend for Exelixis's other non-current assets?

Over 2 years (2020 to 2025), Exelixis's other non-current assets has grown at a -100.0% compound annual growth rate (CAGR), from $73.41M to $0.

Exelixis EXEL Other Non-Current Assets

Other Non-Current Assets at other companies

Eli LillyLLY

$7.23B+19.0%

Summit TherapeuticsSMMT

$8.23M+98.6%

IncyteINCY

$24.49M-18.8%

Ionis PharmaceuticalsIONS

$135.56M+2.8%

BridgeBio PharmaBBIO

$18.62M+12.1%

Neurocrine BiosciencesNBIX

$20.1M-8.6%

Other financials

Income statement

See full

Revenue$610.8M+10.0%

Gross profit$590.9M+10.2%

Operating income$251.3M+34.5%

Net income$210.5M+31.9%

EPS (diluted)$0.79+43.6%

Balance sheet

See full

Cash & equivalents$226.2M+23.1%

Total debt$169.5M-9.4%

Total equity$1.9B-9.2%

Total assets$2.6B-8.6%

Cash flow

See full

Operating cash flow$251.8M+19.1%

CapEx$1.5M-48.9%

Free cash flow$250.3M+20.1%

Valuation

See full

Market cap$13.05B+10.1%

Enterprise value$12.99B+9.5%

P/E15.7×-2.8×

P/S5.5×+0.3×

Profitability

See full

Gross margin96.4%-0.3pp

Operating margin39.4%+6.3pp

Net margin35.1%+7.1pp

FCF margin38.6%+2.9pp

Returns & leverage

See full

Return on equity41%+10.8pp

Debt / equity0.1×0.0×

Current ratio3.3×-0.2×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerAssetNetNoncurrent.

The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Exelixis's other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Exelixis's other non-current assets?: Exelixis (EXEL) reported other non-current assets of $0 in Q1 2026.
What is the long-term trend for Exelixis's other non-current assets?: Over 2 years (2020 to 2025), Exelixis's other non-current assets has grown at a -100.0% compound annual growth rate (CAGR), from $73.41M to $0.